Your letter to the FDA was valuable at the November 2019 hearings (on mercury amalgam) – a pharmacist who has intensely studied pharmacology. I was the one who stood and read it into the record.
Your letter to the FDA was valuable at the November 2019 hearings (on mercury amalgam) – a pharmacist who has intensely studied pharmacology. I was the one who stood and read it into the record.